Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.
2.

Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells.

Markaverich BM, Shoulars K, Rodriguez MA.

Int J Biomed Sci. 2011;7(2):101-111.

3.

Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

Markaverich BM, Vijjeswarapu M, Shoulars K, Rodriguez M.

J Steroid Biochem Mol Biol. 2010 Oct;122(4):219-31. doi: 10.1016/j.jsbmb.2010.06.006. Epub 2010 Jun 15.

4.

Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

Shoulars K, Rodriguez MA, Thompson T, Markaverich BM.

J Steroid Biochem Mol Biol. 2010 Jan;118(1-2):41-50. doi: 10.1016/j.jsbmb.2009.09.016. Epub 2009 Oct 27.

5.

Regulation of the nitric oxide pathway genes by tetrahydrofurandiols: microarray analysis of MCF-7 human breast cancer cells.

Shoulars K, Rodriguez MA, Thompson T, Turk J, Crowley J, Markaverich BM.

Cancer Lett. 2008 Jun 18;264(2):265-73. doi: 10.1016/j.canlet.2008.01.048. Epub 2008 Mar 17.

6.

Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation.

Markaverich BM, Crowley J, Rodriquez M, Shoulars K, Thompson T.

Environ Health Perspect. 2007 Dec;115(12):1727-31.

7.

Tetrahydrofurandiols (THF-diols), leukotoxindiols (LTX-diols), and endocrine disruption in rats.

Markaverich BM, Alejandro M, Thompson T, Mani S, Reyna A, Portillo W, Sharp J, Turk J, Crowley JR.

Environ Health Perspect. 2007 May;115(5):702-8. Epub 2007 Jan 29.

8.
9.

Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4.

Shoulars K, Rodriguez MA, Crowley J, Turk J, Thompson T, Markaverich BM.

J Steroid Biochem Mol Biol. 2006 Apr;99(1):1-8. Epub 2006 Apr 18.

PMID:
16621524
10.

Leukotoxin diols from ground corncob bedding disrupt estrous cyclicity in rats and stimulate MCF-7 breast cancer cell proliferation.

Markaverich BM, Crowley JR, Alejandro MA, Shoulars K, Casajuna N, Mani S, Reyna A, Sharp J.

Environ Health Perspect. 2005 Dec;113(12):1698-704.

11.

Disruption of male sexual behavior in rats by tetrahydrofurandiols (THF-diols).

Mani SK, Reyna AM, Alejandro MA, Crowley J, Markaverich BM.

Steroids. 2005 Oct;70(11):750-4.

PMID:
15927221
12.

Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex.

Shoulars K, Rodrigues MA, Crowley JR, Turk J, Thompson T, Markaverich BM.

J Steroid Biochem Mol Biol. 2005 Jun;96(1):19-30.

PMID:
15878266
13.

Identification of nuclear type II [(3)H]estradiol binding sites as histone H4.

Shoulars K, Brown T, Alejandro MA, Crowley J, Markaverich BM.

Biochem Biophys Res Commun. 2002 Sep 6;296(5):1083-90.

PMID:
12207884
14.

Identification of an endocrine disrupting agent from corn with mitogenic activity.

Markaverich BM, Alejandro MA, Markaverich D, Zitzow L, Casajuna N, Camarao N, Hill J, Bhirdo K, Faith R, Turk J, Crowley JR.

Biochem Biophys Res Commun. 2002 Mar 1;291(3):692-700.

PMID:
11855846
15.
16.

Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats.

Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely OM, O'Malley BW, Medina D.

Carcinogenesis. 1998 Sep;19(9):1573-81.

PMID:
9771927
17.
18.
19.

Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats.

Markaverich BM, Webb B, Densmore CL, Gregory RR.

Environ Health Perspect. 1995 Jun;103(6):574-81.

20.

An improved method for the quantification and recovery of rat uterine nuclear type II [3H]estradiol binding sites immobilized on a glass fiber matrix.

Densmore CL, Tiller AA, Gregory RR, Schauweker TH, Webb B, Markaverich BM.

Steroids. 1995 Feb;60(2):214-9.

PMID:
7618188
21.

Chromatographic resolution of the type II estrogen binding site and a tyrosinase-like enzymatic activity from rat uterine nuclei.

Densmore CL, Schauweker TH, Gregory RR, Webb B, Garcia E, Markaverich BM.

Steroids. 1994 Apr;59(4):282-7.

PMID:
8079383
22.
23.

Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.

Markaverich BM, Schauweker TH, Gregory RR, Varma M, Kittrell FS, Medina D, Varma RS.

Cancer Res. 1992 May 1;52(9):2482-8.

24.

Preliminary characterization and partial purification of rat uterine nuclear type II Binding sites.

Markaverich BM, Gregory RR.

Biochem Biophys Res Commun. 1991 Jun 28;177(3):1283-90.

PMID:
2059216
25.

Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.

Markaverich BM, Gregory RR, Alejandro M, Kittrell FS, Medina D, Clark JH, Varma M, Varma RS.

Cancer Res. 1990 Mar 1;50(5):1470-8.

26.

Intracellular [3H]dopamine binding sites in normal and malignant cells: relationships to cell proliferation.

Markaverich BM, Gregory RR, Alejandro MA.

Biochem Biophys Res Commun. 1989 Nov 30;165(1):391-400.

PMID:
2590236
27.

Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth.

Markaverich BM, Gregory RR, Alejandro MA, Varma RS, Johnson GA, Middleditch BS.

J Steroid Biochem. 1989 Nov;33(5):867-76.

PMID:
2601331
28.

Characterization and partial purification of an estrogen type II binding site in chick oviduct cytosol.

Densmore CL, Markaverich BM, O'Malley BW, Clark JH.

Biochemistry. 1989 Sep 19;28(19):7788-96.

PMID:
2611214
29.

Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.

Markaverich BM, Gregory RR, Alejandro MA, Clark JH, Johnson GA, Middleditch BS.

J Biol Chem. 1988 May 25;263(15):7203-10.

30.

Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition.

Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, Middleditch BS, Clark JH.

J Steroid Biochem. 1988;30(1-6):71-8.

PMID:
3386279
31.

Cytosol type II sites in the rat uterus: interaction with an endogenous ligand.

Markaverich BM, Adams NR, Roberts RR, Alejandro M, Clark JH.

J Steroid Biochem. 1987 Dec;28(6):599-608.

PMID:
2826918
32.

Uterine type II estrogen-binding sites are not of eosinophil origin.

Markaverich BM, Roberts RR, Alejandro MA, Clark JH.

J Biol Chem. 1986 Jan 5;261(1):142-6.

33.

An endogenous ligand for type II binding sites in normal and neoplastic tissues.

Clark JH, Markaverich BM.

Adv Exp Med Biol. 1986;196:305-15.

PMID:
3716924
34.
35.

The agonistic and antagonistic actions of estriol.

Clark JH, Markaverich BM.

J Steroid Biochem. 1984 Apr;20(4B):1005-13.

PMID:
6202959
36.

The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites.

Markaverich BM, Roberts RR, Alejandro M, Clark JH.

Endocrinology. 1984 Mar;114(3):814-20.

PMID:
6697964
37.

Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei.

Markaverich BM, Roberts RR, Finney RW, Clark JH.

J Biol Chem. 1983 Oct 10;258(19):11663-71.

38.

An endogenous ligand for the triphenylethylene antiestrogen binding site.

Clark JH, Winneker RC, Guthrie SC, Markaverich BM.

Endocrinology. 1983 Sep;113(3):1167-9.

PMID:
6872955
39.
40.

Heterogeneity of estrogen binding sites in mammary tumors.

Clark JH, Watson CS, Markaverich BM, Syne JS, Panko WB.

Breast Cancer Res Treat. 1983;3(1):61-5.

PMID:
6871482
41.

The agonistic and antagonistic effects of short acting estrogens: a review.

Clark JH, Markaverich BM.

Pharmacol Ther. 1983;21(3):429-53. Review.

PMID:
6356176
42.
44.

Effects of estradiol-17 alpha on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites and uterine growth.

Clark JH, Williams M, Upchurch S, Eriksson H, Helton E, Markaverich BM.

J Steroid Biochem. 1982 Feb;16(2):323-8.

PMID:
7078167
45.

Relationships between type I and II estradiol binding sites and estrogen induced responses.

Clark JH, Markaverich BM.

J Steroid Biochem. 1981 Dec;15:49-54. No abstract available.

PMID:
7339275
46.

Quantitation of nuclear-estrogen receptors in the rat uterus by [3H]-estradiol exchange.

Markaverich BM, Clark JH.

J Steroid Biochem. 1981 Dec;15:289-92. No abstract available.

PMID:
7339255
47.
48.

Differential stimulation of uterine cells by nafoxidine and clomiphene: relationship between nuclear estrogen receptors and type II estrogen binding sites and cellular growth.

Markaverich BM, Upchurch S, McCormack SA, Glasser SR, Clark JH.

Biol Reprod. 1981 Feb;24(1):171-81. No abstract available.

PMID:
7470541
49.

Progesterone and dexamethasone antagonism of uterine growth: a role for a second nuclear binding site for estradiol in estrogen action.

Markaverich BM, Upchurch S, Clark JH.

J Steroid Biochem. 1981 Feb;14(2):125-32. No abstract available.

PMID:
7206703
50.

Oestrogenic stimulation of uterine growth: relation to oestrogen receptor binding and the stimulation of nuclear type II oestradiol binding sites.

Clark JH, Upchurch S, Markaverich BM.

J Endocrinol. 1981;89 Suppl:47P-57P. No abstract available.

PMID:
7241020

Supplemental Content

Loading ...
Support Center